Evaxion Biotech A/S

Research Evaxion Biotech A/S (EVAX) on Bullrun: market cap USD 26.69M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerEVAX
• ExchangeNASDAQ
• CountryDenmark
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 26.69M
• Financial periodQ1 2026
• RevenueUSD 7.53M
• Net income-USD 3.63M

Valuation Snapshot

latest market cap is USD 26.69M.

About Evaxion Biotech A/S

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.

Frequently asked questions

What is Evaxion Biotech A/S's market cap?

Evaxion Biotech A/S's market capitalization is USD 26.69M.

What does Evaxion Biotech A/S do?

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors;